ReviewFrontiers in immunology2026
The alarmin-ILC2 axis as a candidate mechanism for persistent olfactory dysfunction in allergic rhinitis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is an underrecognized contributor to olfactory dysfunction (OD). Although smell loss in AR is commonly attributed to conductive obstruction, some patients exhibit persistent or disproportionate hyposmia despite improvement in nasal congestion, suggesting that additional sensorineural mechanisms may exist. Hypothesis: We hypothesize that, in a subset of patients with persistent, moderate-to-severe, type 2-high AR-associated OD without macroscopic olfactory cleft obstruction, allergen-induced epithelial stress in the olfactory cleft may activate an alarmin-ILC2/type 2 neuroimmune pathway. IL-33 and thymic stromal lymphopoietin (TSLP) released from epithelial or sustentacular cell populations, together with IL-25 and lipid mediator signals from tuft-like microvillar cells, may engage group 2 innate lymphoid cells (ILC2s) as early amplifiers within a broader type 2 inflammatory network. This response is proposed to contribute to three candidate injury modules: IL-13/STAT6-associated horizontal basal cell fate bias, IL-5/eosinophil-associated olfactory sensory neuron injury, and IL-4/IL-13-associated sustentacular cell dysfunction. Rationale and evidence gap: Current support is indirect and derives from murine olfactory inflammation models, ex vivo olfactory preparations, human non-olfactory nasal mucosal studies, and chronic rhinosinusitis with nasal polyps (CRSwNP) studies used as mechanistic analogies. None of the proposed mechanisms has been directly validated in human AR olfactory cleft tissue, which together represent the central evidence gap. Implications: The model generates falsifiable predictions regarding olfactory cleft alarmins, type 2 cytokines, ILC2-like immune niches, basal cell transcriptional state, and biomarker-linked responses in future proof-of-mechanism studies. It is presented as a hypothesis to guide future non-invasive biomarker studies, ethically feasible tissue analyses, organoid experiments, and biomarker-enriched proof-of-mechanism trials, not as a validated disease mechanism or current treatment recommendation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.